Halozyme Therapeutics (NASDAQ:HALO) Director Sells $294,720.00 in Stock
MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares of the company's stock, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NASDAQ:HALO